Transparency Issues Floor Novo Nordisk's Tresiba At IQWiG
This article was originally published in The Pink Sheet Daily
Executive Summary
IQWiG has said that Novo Nordisk's refusal to make public part of its dossier for its diabetes therapy Tresiba represents a lack of transparency and makes the drug impossible to recommend.